2,664 reports of this reaction
2.0% of all LAMOTIRIGINE reports
#11 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #11 most commonly reported adverse reaction for LAMOTIRIGINE, manufactured by Actavis Pharma, Inc.. There are 2,664 FDA adverse event reports linking LAMOTIRIGINE to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 2.0% of all 130,106 adverse event reports for this drug.
Patients taking LAMOTIRIGINE who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for LAMOTIRIGINE, but still significant enough to appear in the safety profile.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for LAMOTIRIGINE:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 2,664 FDA reports for LAMOTIRIGINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 2.0% of all adverse event reports for LAMOTIRIGINE, making it a notable side effect.
If you experience foetal exposure during pregnancy while taking LAMOTIRIGINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.